BioLife Solutions (BLFS) HR chief awarded 23,548 shares

Rhea-AI Filing Summary

BioLife Solutions Chief Human Resources Officer Sarah Aebersold received a grant of 23,548 shares of common stock at $0.00 per share, tied to the company’s 2023 Omnibus Performance Incentive Plan. About 156% of the target shares vested based on relative total shareholder return, and 5,734 shares were withheld at $22.65 per share to cover taxes, leaving her with 93,579 shares directly owned.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Aebersold Sarah

Role Chief Human Resources Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	23,548	$0.00	--
Tax Withholding	Common Stock	5,734	$22.65	$130K

Holdings After Transaction: Common Stock — 99,313 shares (Direct)

Footnotes (1)

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aebersold Sarah

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		23,548	A	(1)	99,313	D
Common Stock	02/24/2026		F		5,734	D	$22.65(2)	93,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

2. Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.

Remarks:

	/s/ Sarah Aebersold	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did BLFS report for Sarah Aebersold?

Sarah Aebersold received a grant of 23,548 BioLife Solutions shares at $0.00 and had 5,734 shares withheld at $22.65 to cover taxes. After these transactions, she directly owned 93,579 common shares, reflecting equity-based compensation rather than open-market trading.

Was the BLFS insider transaction a stock purchase or sale?

The activity combined an equity award and a tax withholding. Aebersold acquired 23,548 common shares through a grant, then disposed of 5,734 shares withheld to satisfy tax obligations. No open-market buying or selling was reported; both movements stemmed from an incentive plan vesting event.

How many BLFS shares does Sarah Aebersold own after these transactions?

Following the grant and tax withholding, Aebersold directly owns 93,579 shares of BioLife Solutions common stock. Her holdings reflect equity compensation under the 2023 Omnibus Performance Incentive Plan, rather than purchases on the market or discretionary share sales for personal portfolio reasons.

What plan governed Sarah Aebersold’s BLFS stock grant and vesting terms?

The grant was issued under the BioLife Solutions 2023 Omnibus Performance Incentive Plan. Vesting depended on total shareholder return from January 1, 2024 through December 31, 2025 versus selected peers, with approximately 156% of the originally granted shares ultimately vesting under the plan’s performance conditions.

Why were 5,734 BLFS shares disposed of in Sarah Aebersold’s filing?

The 5,734 shares were withheld by the company to cover tax withholding obligations tied to the vesting of a market-based restricted stock award. This tax-withholding disposition did not represent an open-market sale, but an automatic share reduction associated with a compensation event.